SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-Q’ for 9/30/15 – ‘EX-10.1’

On:  Tuesday, 11/10/15, at 5:11pm ET   ·   For:  9/30/15   ·   Accession #:  1479290-15-10   ·   File #:  1-36297

Previous ‘10-Q’:  ‘10-Q’ on 8/7/15 for 6/30/15   ·   Next:  ‘10-Q’ on 5/10/16 for 3/31/16   ·   Latest:  ‘10-Q’ on 11/8/23 for 9/30/23   ·   8 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/10/15  Revance Therapeutics, Inc.        10-Q        9/30/15   66:5.6M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    644K 
 2: EX-10.1     Material Contract                                   HTML     28K 
 3: EX-10.2     Material Contract                                   HTML     68K 
 4: EX-10.3     Material Contract                                   HTML     64K 
 5: EX-10.4     Material Contract                                   HTML     70K 
 6: EX-10.5     Material Contract                                   HTML     68K 
 7: EX-10.6     Material Contract                                   HTML     70K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
45: R1          Document and Entity Information                     HTML     39K 
35: R2          Condensed Consolidated Balance Sheets               HTML     99K 
43: R3          Condensed Consolidated Balance Sheets               HTML     31K 
                (Parenthetical)                                                  
48: R4          Condensed Consolidated Statement of Operations and  HTML     92K 
                Comprehensive Loss                                               
61: R5          Consolidated Statements of Cash Flows               HTML    171K 
37: R6          The Company and Basis of Presentation               HTML     36K 
42: R7          Summary of Significant Accounting Policies          HTML     39K 
32: R8          Medicis Settlement                                  HTML     30K 
25: R9          Cash Equivalents and Investments                    HTML     82K 
62: R10         Fair Value Measurements                             HTML     82K 
50: R11         Notes Payable and Financing Obligation              HTML     41K 
49: R12         Convertible Notes, Warrants, and Related            HTML     26K 
                Derivatives                                                      
54: R13         Interest Expense                                    HTML     62K 
55: R14         Commitments and Contingencies                       HTML     40K 
53: R15         Warrants                                            HTML     22K 
56: R16         Equity                                              HTML    105K 
44: R17         Net Loss per Share Attributable to Common           HTML     62K 
                Stockholders                                                     
46: R18         Subsequent Events                                   HTML     25K 
52: R19         Summary of Significant Accounting Policies          HTML     52K 
                (Policies)                                                       
66: R20         Cash Equivalents and Investments (Tables)           HTML     78K 
58: R21         Fair Value Measurements (Tables)                    HTML     79K 
39: R22         Notes Payable and Financing Obligation (Tables)     HTML     27K 
51: R23         Interest Expense (Tables)                           HTML     60K 
41: R24         Commitments and Contingencies (Tables)              HTML     28K 
22: R25         Equity (Tables)                                     HTML     92K 
59: R26         Net Loss per Share Attributable to Common           HTML     62K 
                Stockholders (Tables)                                            
63: R27         The Company and Basis of Presentation - Additional  HTML     60K 
                Information (Detail)                                             
28: R28         Medicis Settlement - Additional Information         HTML     49K 
                (Detail)                                                         
27: R29         Cash Equivalents and Investments (Details)          HTML     44K 
30: R30         Fair Value Measurements - Schedule of Fair Value    HTML     53K 
                of Financial Instruments (Detail)                                
31: R31         Fair Value Measurements - Summary of Changes in     HTML     27K 
                Fair Value of Financial Instruments (Detail)                     
33: R32         Notes Payable and Financing Obligation - Hercules   HTML     54K 
                Notes Payable (Detail)                                           
21: R33         Notes Payable and Financing Obligation - Essex      HTML     58K 
                Capital Notes (Detail)                                           
57: R34         Notes Payable and Financing Obligation - Summary    HTML     29K 
                of Aggregate Total Future Minimum Lease Payments                 
                under the Financing Obligation (Detail)                          
38: R35         Convertible Notes, Warrants, and Related            HTML     61K 
                Derivatives - Additional Information (Detail)                    
40: R36         Interest Expense - Summary of Interest Expense by   HTML     42K 
                Cash and Non-Cash Components (Detail)                            
24: R37         Commitments and Contingencies - Additional          HTML     34K 
                Information (Detail)                                             
65: R38         Commitments and Contingencies - Schedule of Future  HTML     38K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
18: R39         Warrants - Additional Information (Detail)          HTML     28K 
34: R40         Equity - Additional Information (Detail)            HTML     69K 
60: R41         Equity - Fair Value Assumptions (Details)           HTML     44K 
23: R42         Equity - Schedule of Stock-based Compensation       HTML     30K 
                Expense (Details)                                                
26: R43         Equity - Schedule of Accumulated Other              HTML     33K 
                Comprehensive Income (Details)                                   
29: R44         Net Loss per Share Attributable to Common           HTML     45K 
                Stockholders - Schedule of Computation of Basic                  
                and Diluted Net Income (Loss) Per Share                          
                Attributable to Common Stockholders (Detail)                     
36: R45         Net Loss per Share Attributable to Common           HTML     34K 
                Stockholders - Summary of Common Stock Equivalents               
                Excluded from Computation of Diluted Net Income                  
                (Loss) Per Share (Detail)                                        
20: R46         Subsequent Events (Details)                         HTML     46K 
64: XML         IDEA XML File -- Filing Summary                      XML    106K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX     58K 
12: EX-101.INS  XBRL Instance -- rvnc-20150930                       XML   1.30M 
14: EX-101.CAL  XBRL Calculations -- rvnc-20150930_cal               XML    173K 
15: EX-101.DEF  XBRL Definitions -- rvnc-20150930_def                XML    354K 
16: EX-101.LAB  XBRL Labels -- rvnc-20150930_lab                     XML   1.10M 
17: EX-101.PRE  XBRL Presentations -- rvnc-20150930_pre              XML    636K 
13: EX-101.SCH  XBRL Schema -- rvnc-20150930                         XSD    123K 
47: ZIP         XBRL Zipped Folder -- 0001479290-15-000010-xbrl      Zip    149K

‘EX-10.1’   —   Material Contract

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 <!   C:   C: 
  Exhibit  
[ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Exhibit 10.1
SECOND AMENDMENT
to
DEVELOPMENT AND SUPPLY AGREEMENT
between
REVANCE THERAPEUTICS, INC.
and
HOSPIRA WORLDWIDE, INC.
This Second Amendment to the Development and Supply Agreement (“Amendment”) is made and effective as of the 31st day of August, 2015 (“Amendment Effective Date”), by and between Revance Therapeutics, Inc. (“Revance”) and Hospira Worldwide, Inc., (“Hospira”), each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
RECITALS
WHEREAS, Revance and Hospira are Parties to that certain Development and Supply Agreement dated as of December 11, 2009 (the “Agreement”); and
WHEREAS, by an agreement dated May 29, 2013 (“First Amendment”) the Parties have amended Section 9.3 of the Agreement; and
WHEREAS, the Parties now desire further to amend Section 9.3 of the Agreement under the terms and conditions set forth below.
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree that the Agreement is amended as follows:
1)
Section 9.3. Section 9.3, as modified by the First Amendment, is hereby replaced in its entirety with the following amended Section 9.3:
9.3    Failure to Obtain Regulatory Approval. Either party may terminate this Agreement by giving to the other party twelve (12) months’ prior written notice if the Product has not received FDA regulatory approval by [***].
2)
Except as expressly amended herein, all other terms and conditions of the Agreement shall remain in full force and effect, and enforceable in accordance with its terms. The terms and conditions of this Amendment are hereby incorporated into and made a part of the Agreement.
3)
This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. The parties may sign and deliver this Amendment by facsimile or sent by electronic mail in portable document format (PDF) and a reproduction of this Amendment made by facsimile or PDF will have the same effect as a signed and delivered original version.
[SIGNATURE PAGE FOLLOWS]

1.
 

IN WITNESS WHEREOF, the Parties intending to be bound by the terms and conditions hereof have caused this Amendment to be signed by their duly authorized representatives as of the date first above written.
HOSPIRA WORLDWIDE, INC.
REVANCE THERAPEUTICS, INC.
 
 
By:   /s/ Karen Blair            
   (Signature)
By:   /s/ L. Daniel Browne         
   (Signature)
 
 
Name: Karen Blair
Name: L. Daniel Browne
 
 
Title: President
   One 2 One Contract Manufacturing Services
Title: President & CEO
   


2.
[ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
 

Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:11/10/15None on these Dates
For Period end:9/30/15
5/29/13
12/11/09
 List all Filings 

8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Revance Therapeutics, Inc.        S-8         2/29/24    4:123K
 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M
 2/28/23  Revance Therapeutics, Inc.        S-8         2/28/23    5:192K
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
 2/28/22  Revance Therapeutics, Inc.        S-8         2/28/22    5:197K
 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M
 1/29/21  Revance Therapeutics, Inc.        S-8         1/29/21    3:137K
↑Top
Filing Submission 0001479290-15-000010   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., Apr. 25, 9:38:09.2am ET